Peripheral blood immunoinflammatory biomarkers: prospective predictors of postoperative long-term survival and chronic postsurgical pain in breast cancer

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Jan. 29, 2025

Background Tumor progression and chronic postsurgical pain (CPSP) in patients with breast cancer are both significantly influenced by inflammation. The associations between immunoinflammatory biomarkers long-term survival, as well CPSP, remain ambiguous. This study examined the predictive value of for survival CPSP. Methods Data on clinicopathological characteristics perioperative peripheral blood 80 who underwent surgery were retrospectively collected. Optimal cut-off values preoperative biomarkers, including systemic immune-inflammation index (SII), inflammation response (SIRI), neutrophil-to-lymphocyte ratio (NLR), pan-immune-inflammation (PIV), established via receiver operating characteristic (ROC) curves. Kaplan−Meier curves Cox regression analysis used to evaluate relationships survival. among neutrophil count (NEU), monocyte (MONO), lymphocyte (LYM), platelet (PLT), SII, SIRI, NLR, PIV, dynamic changes cell counts, CPSP further assessed using logistic analysis. Results revealed a considerable prolongation disease-free (DFS) overall (OS) low PIV groups. Multivariate that only an elevated SIRI was independent risk factor postoperative DFS (HR=8.890, P=0.038). incidence 28.75%. Univariate body mass (BMI), NEU, MONO, negatively correlated occurrence whereas subsequent multivariate BMI independently associated (OR=0.262, P=0.023). Conclusion Elevated poor after surgery. In contrast, had limited potential predicting

Language: Английский

Comprehensive Evaluation of Inflammatory Biomarkers in Cervical Cancer Treated with Chemoradiotherapy

Current Oncology, Journal Year: 2025, Volume and Issue: 32(1), P. 39 - 39

Published: Jan. 13, 2025

Objective: Inflammatory biomarkers have been shown to possess both prognostic and predictive significance in various cancers. Among the emerging biomarkers, pan-immune-inflammation value (PIV) has recently introduced as a novel indicator representing immune response systemic inflammatory state. This study aims comprehensively evaluate of on survival outcomes cervical cancer patients undergoing chemoradiotherapy. Methods: A total 90 who had undergone chemoradiotherapy for were included. Data demographics, treatment protocols, pre-treatment blood parameters, collected. The association between was investigated through univariate multivariate analyses. Results: analysis identified following predictors progression-free (PFS): neutrophil–lymphocyte ratio (NLR), platelet–lymphocyte (PLR), monocyte–lymphocyte (MLR), immune-inflammation index (SII), PIV, C-reactive protein (CRP), albumin, tumor size. Multivariate revealed that only PIV significantly predicted PFS (HR 3.05, 95% CI 1.0 9.3, p = 0.04). In analysis, several variables overall (OS), including NLR, PLR, MLR, SII, CRP, LDH, size, Eastern Cooperative Oncology Group Performance Status (ECOG PS). CRP 3.41, 1.5 7.7, 0.003) ECOG PS 4.78, 1.3 17.3, 0.01) OS, with approaching statistical 2.56, 0.8 7.6, 0.09). Conclusions: provides first comprehensive biomarkers. Many these demonstrated definitive evaluated, most predictive, warranting further exploration future research.

Language: Английский